MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
TiLE (Time Lapse Eeva) Clinical Trial
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 976
- Registration Number
- NCT02417441
- Locations
- 🇨🇦
One Fertility, Burlington, Ontario, Canada
🇨🇦Cambrian Wellness Centre, Calgary, Alberta, Canada
🇨🇦Mount Sinai Hospital, Toronto, Canada
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 8
- Registration Number
- NCT02394782
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 243
- Registration Number
- NCT02383966
- Locations
- 🇩🇪
Research site, Darmstadt, Germany
Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 32
- Registration Number
- NCT02325713
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
- First Posted Date
- 2014-12-16
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 34
- Registration Number
- NCT02317809
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 31
- Registration Number
- NCT02316197
- Locations
- 🇳🇱
Erasmus Medisch Centrum - Parent, Rotterdam, Netherlands
🇳🇱Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇳🇱VU Medisch Centrum - Dept of Medical Oncology, Amsterdam, Netherlands
Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 48
- Registration Number
- NCT02315352
- Locations
- 🇹🇿
Ifakara Health Institute, Ikwiriri, Rufiji, Tanzania
Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 36
- Registration Number
- NCT02271984
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT02255110
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 106
- Registration Number
- NCT02254304
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
© Copyright 2024. All Rights Reserved by MedPath